CVA Family Office’s Labcorp LH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$42.4K Buy
159
+111
+231% +$30.1K ﹤0.01% 633
2025
Q4
$12K Sell
48
-15
-24% -$3.98K ﹤0.01% 767
2025
Q3
$18.1K Buy
63
+15
+31% +$4.02K ﹤0.01% 717
2025
Q2
$12.6K Buy
48
+12
+33% +$2.92K ﹤0.01% 762
2025
Q1
$8.38K Buy
36
+8
+29% +$1.94K ﹤0.01% 827
2024
Q4
$6.42K Buy
28
+17
+155% +$3.9K ﹤0.01% 849
2024
Q3
$2.46K Buy
11
+4
+57% +$879 ﹤0.01% 954
2024
Q2
$1.43K Buy
7
+2
+40% +$407 ﹤0.01% 1014
2024
Q1
$1.09K Hold
5
﹤0.01% 992
2023
Q4
$1.14K Buy
+5
New +$1.05K ﹤0.01% 972
2023
Q3
Sell
-6
Closed -$1.21K 634
2023
Q2
$1.21K Buy
+6
New +$1.16K ﹤0.01% 916
2023
Q1
Sell
-6
Closed -$1.18K 994
2022
Q4
$1.18K Sell
6
-41
-87% -$8.01K ﹤0.01% 859
2022
Q3
$8K Hold
47
﹤0.01% 660
2022
Q2
$9K Sell
47
-5
-10% -$1.07K ﹤0.01% 657
2022
Q1
$12K Hold
52
﹤0.01% 649
2021
Q4
$14K Buy
+52
New +$12.9K ﹤0.01% 590
2021
Q3
Sell
-52
Closed -$12K 637
2021
Q2
$12K Buy
52
+11
+27% +$2.51K ﹤0.01% 618
2021
Q1
$9K Buy
+41
New +$8.23K ﹤0.01% 539

Other funds holding LH

CVA Family Office's LH Position: Q1 2026 in Review

CVA Family Office increased its Labcorp (LH) stake by 231% in Q1 2026, buying an estimated $30.1K and bringing the position to 159 shares worth $42.4K. The position accounts for ﹤0.01% of the portfolio, ranked #633.

CVA Family Office first reported a position in LH in Q1 2021 and has held it in 18 quarters since. 1,032 funds tracked by Wall St. Rank hold LH as of Q1 2026.

  • CVA Family Office held 159 shares of Labcorp worth $42.4K as of Q1 2026.
  • CVA Family Office bought 111 Labcorp shares in Q1 2026, an estimated $30.1K.
  • Labcorp made up ﹤0.01% of CVA Family Office's portfolio in Q1 2026, its #633 holding.
  • CVA Family Office first reported a position in Labcorp in Q1 2021 and has held it in 18 quarters since.
  • 1,032 funds tracked by Wall St. Rank held Labcorp as of Q1 2026.

Based on CVA Family Office's 13F filing for Q1 2026, filed 29 Apr 2026.